×
About 33,063 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  10,284 results

Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed...
https://doi.org/10.1111/bjh.18249
British Journal of Haematology; Böckle D, Tabares P et. al.

May 19th, 2022 - Measurement of minimal residual disease (MRD) by next-generation flow cytometry (NGF) is an important tool to define deep responses in multiple myeloma (MM). However, little is known about the value of combining NGF with functional imaging and its...

Novel immunotherapies in multiple myeloma.
https://doi.org/10.1007/s12185-022-03365-1 10.1007/s12185-020-02828-7 10.1007/s12185-020-02828-7 10.1016/j.pathol.2021.02.003 10.1158/1078-0432.CCR-10-1822 10.3324/haematol.2017.163766 10.1056/NEJMoa1709974 10.3390/cancers13092018 10.1046/j.1365-2141.1998.00525.x 10.1016/S0145-2126(01)00192-8 10.1016/j.leukres.2004.06.003 10.1182/blood-2005-09-3671 10.1182/blood.V100.1.230 10.1111/j.1365-2249.2006.03037.x 10.4049/jimmunol.1203373 10.1002/jcp.27172 10.3390/cancers12040924 10.1200/JCO.2015.65.9789 10.1158/1078-0432.CCR-15-0200 10.1016/S2352-3026(19)30110-3 10.1016/S2352-3026(19)30109-7 10.1093/annonc/mdv383 10.1200/JCO.2017.35.15_suppl.TPS8051 10.1016/j.jtct.2020.12.026 10.1158/1078-0432.CCR-15-0304 10.3324/haematol.2013.103085 10.1016/j.immuni.2020.04.011 10.3390/cancers12020305 10.1158/1535-7163.MCT-19-1079 10.4049/jimmunol.2001019 10.1200/JCO.2020.38.15_suppl.3064 10.1158/1078-0432.CCR-06-1603 10.4149/neo_2010_05_455 10.1111/bjh.12943 10.1182/blood.V97.5.1508 10.1182/blood-2007-03-082529 10.1007/s00262-011-1009-3 10.1158/0008-5472.CAN-05-1383 10.1073/pnas.90.8.3539 10.1586/14760584.4.3.259 10.1158/1078-0432.CCR-21-1916 10.1158/1078-0432.CCR-13-0282 10.1056/NEJM198812223192527 10.1093/jnci/86.15.1159 10.1007/s12185-016-2039-6 10.1056/NEJMoa1707447 10.1056/NEJMoa1804980 10.1056/NEJMoa1709866 10.1016/S0140-6736(14)61403-3 10.1126/scitranslmed.3005930 10.1172/JCI85309 10.1158/1078-0432.CCR-12-2422 10.1016/j.smim.2006.04.006 10.1056/NEJMoa1817226 10.1056/NEJMoa2024850 10.1186/s13045-018-0681-6 10.1016/S0140-6736(21)00933-8 10.1182/blood-2021-146200 10.1182/blood-2021-146072 10.1038/s41591-021-01497-1 10.1158/2159-8290.CD-15-1020 10.1182/blood-2015-08-665547 10.1038/s41591-018-0201-9 10.1038/leu.2016.211 10.1200/JCO2101676 10.1182/blood-2017-05-781351 10.1182/bloodadvances.2019000703 10.1038/ncomms8333 10.1182/blood-2021-154170 10.1182/blood-2019-130340 10.1038/s41467-020-16160-5 10.1158/2326-6066.CIR-18-0307 10.1172/JCI86000 10.3390/cells9122666 10.3389/fimmu.2018.02551 10.1016/S2152-2650(21)02229-1 10.1182/blood-2010-06-292243 10.1182/blood-2010-06-292243 10.1038/nm.4431 10.1016/j.bbmt.2019.08.015 10.3324/haematol.2019.229781 10.1111/ejh.13380 10.1038/s41409-019-0451-2 10.1038/nrclinonc.2017.148 10.1038/s41591-021-01564-7 10.1038/nrc3670 10.1182/blood-2004-09-3707 10.1038/nm.3910 10.1182/bloodadvances.2019000194 10.1126/science.aba7365 10.1182/blood-2016-09-737536 10.1016/j.ymthe.2021.08.010 10.1182/blood-2010-04-279893 10.1038/sj.leu.2404444 10.1016/j.imlet.2018.04.005 10.3324/haematol.2018.202200 10.1038/s41375-018-0153-6 10.1038/s41591-018-0010-1 10.1038/s41591-020-1061-7 10.3389/fimmu.2021.732135 10.1093/intimm/dxab091
International Journal of Hematology; Ohmine K, Uchibori R

May 19th, 2022 - For a substantial period, options for the treatment of multiple myeloma (MM) were limited; however, the advent of novel therapies into clinical practice in the 1990s resulted in dramatic changes in the prognosis of the disease. Subsequently, new p...

Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts-A follow-up.
https://doi.org/10.1002/cam4.4816
Cancer Medicine; Holler A, Cicha I et. al.

May 18th, 2022 - Extramedullary plasmacytoma (EMP) is a solitary tumor consisting of neoplastic plasma cells, with very little to no bone marrow involvement. EMPs are usually located in the head and neck region, but can also occur along the digestive tract, in lun...

Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What a...
https://doi.org/10.2174/1568009622666220516102235
Current Cancer Drug Targets; Sak K

May 18th, 2022 - Approval of the first boronic acid group-containing drug, bortezomib, in 2003 for the treatment of multiple myeloma sparked an increased interest of medicinal chemists in boronic acid-based therapeutics. As a result, another boronic acid moiety-ha...

Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myel...
https://doi.org/10.1182/blood.2021015220
Blood Yamamoto C, Minakata D et. al.

May 18th, 2022 - Triplet regimens such as lenalidomide, bortezomib, and dexamethasone (RVd) or thalidomide, bortezomib, and dexamethasone (VTd) are standard induction therapies for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients. The addition ...

see more →

Guidelines  36 results

Management of herpesvirus reactivations in patients with solid tumours and hematologic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475
Annals of Hematology; Henze L, Buhl C et. al.

Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive C...
https://doi.org/10.1016/j.clml.2021.07.028
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

see more →

Drugs  157 results see all →

Clinicaltrials.gov  816 results

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01734928

May 13th, 2022 - The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. T...

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03602612

May 13th, 2022 - Background: Multiple myeloma (MM) is a malignancy of plasma cells. MM is nearly always incurable. T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens. Autologous ...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

May 13th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00339963

May 13th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
https://clinicaltrials.gov/ct2/show/NCT01139476

May 13th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

see more →

News  1,910 results

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

Cilta-Cel Induces Impressive ORR in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-induces-impressive-orr-in-relapsed-refractory-multiple-myeloma

May 3rd, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated strong overall response rate (ORR) and progression-free survival (PFS) results in patients with relapsed or refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207), according ...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

Avoiding the Cliff: Screening for Early-Stage Multiple Myeloma
https://www.medscape.com/viewarticle/964336

May 3rd, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael, and welcome to Medscape InDiscussion: Multiple Myeloma. Today we're talking about screening for early-stage multiple myeloma, and I think this is...

Frontline Therapy for Multiple Myeloma
https://www.medscape.com/viewarticle/964337

May 3rd, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael, and welcome to Medscape InDiscussion Multiple Myeloma. Today we're talking about frontline therapy for multiple myeloma, and although sometimes w...

see more →

Patient Education  22 results see all →